Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis

Breast Cancer Research and Treatment

Volumn 152, Issue 2, 2015, Pages 231-237

  Ramaswami, Ramya ^a,c   Villarreal, Marcos Daniel ^a   Pitta, Dina Marie ^a   Carpenter, Janet S ^b   Stebbing, Justin ^c   Kalesan, Bindu ^a  

^a Department of Medicine   (United States)

^b INDIANA UNIVERSITY   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Breast cancer; Hot flash; Meta analysis; Review; Symptoms; Venlafaxine

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; CLONIDINE; GABAPENTIN; TAMOXIFEN; VENLAFAXINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR;

ACUPUNCTURE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; FOLLOW UP; HOT FLUSH; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; BREAST TUMOR; COMPLICATION; DISEASE MANAGEMENT; FEMALE; HOT FLASHES;

BREAST NEOPLASMS; DISEASE MANAGEMENT; FEMALE; HOT FLASHES; HUMANS; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE;

EID: 84946488431     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3465-5     Document Type: Review

References (38)

1. Couzi RJ, Helzisouer KJ, Fetting JH (1995) Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13(11):2737–2744
2. Stan D, Loprinzi CL, Ruddy KJ (2013) Breast cancer survivorship. Hematol Oncol Clin North Am 27(4):805–827
3. Kronenberg F (1994) Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 29(3–4):319–336
4. Hickey M, Saunders CM, Stuckey BG (2005) Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet oncol 6(9):687–695
5. Rance NE, Dacks PA, Mittleman-Smith MA et al (2013) Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot fluhes. Front Neuroendocrinol 34(3):211–227
6. Krause MS, Nakajima ST (2015) Hormonal and nonhormal treatment of vasomotor symptoms. Obstet Gynecol Clin North Am 42(1):163–179
7. Quella SK, Loprinzi CL, Sloan JA et al (1998) Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 82(9):1784–1788
8. Goodwin JW, Green SJ, Moinpour CM et al (2008) Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. J Clin Oncol 26(10):1650–1656
9. Holmberg L, Anderson H, For the HABITS Steering and Data Monitoring Committees (2004) HABITS (hormonal replacement therapy after breast cancer–is it safe?), a randomised comparision: trial stopped. Lancet 363:453–455
10. Stearns V, Isaacs C, Rowland J et al (2000) A pilot trial assessing the efficacu of paroxetine hydrocholride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 11:17–22
11. Pandya KJ, Thummala AR, Griggs JJ et al (2004) Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Res Treat 83:87–89
12. Loprinzi CL, Kugler JW, Sloan JA et al (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356:2059–2063
13. Weber L, Thacker HL (2014) Paroxetine: a first for selective serotonin reuptake inhibitors—a new use: approved for vasomotor symptoms in postmenopausal women. Womens Health (London Engl) 10(2):147–154
14. Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30–39
15. Binkhorst L, Mathijssen RH, van Herk-Sukel MP et al (2013) Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat 139(3):923–929
16. Boekhout AH, Vincent AD, Dalesio OB et al (2011) Management of hot flashes in patients who have breast cancer with Venladaxine and Clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 29:3862–3868
17. Walker EM, Rodriguez AI, Kohn B et al (2010) Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial. J Clin Oncol 28:634–640
18. Yamaguchi N, Okajima Y, Fujii T et al (2013) The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol 139:1701–1707
19. Juni P, Altman DG, Egger M (2001) Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323:42–46
20. Hollis S, Campbell F (1999) What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319:670–674
21. Sloan JA, Loprinzi CL, Novotny PJ et al (2001) Methodologic lessons learned from hot flash studies. J Clin Oncol 19(23):4280–4290
22. Stradling C, Chen YF, Russell T et al (2012) The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis. PLoS One 7(6):e38121
23. Carpenter JS, Stomiolo AM, Johns S et al (2007) Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 12:124–135
24. Buijs C, Mom CH, Willemse PHB, Boezen HM et al (2009) Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 115:573–580
25. Elbourne DR, Altman DG, Higgins JPT et al (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31(1):140–149
26. Da Costa BR, Rutjes AWS, Johnston BC et al (2012) Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study. Int J Epidemiol 41(5):1445–1459
27. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
28. Nüesch E, Trelle S, Reichenbach S et al (2010) Small study effects in meta-analyses of osteoarthritis trials: a meta-epidemiological study. BMJ 341:c3515
29. Bordeleau L, Pritchard KI, Loprinzi CL et al (2010) Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 28:5147–5152
30. Loibl S, Schwedler K, von Minckwitz G et al (2007) Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patinets—a double-blind, randomized study. Ann Oncol 18:689–693
31. Harbord RM, Harris RJ, Sterne JAC (2009) Updated tests for small-study effects in meta-analyses. Stata J 9(2):197–210
32. Haddad NE, Palesh O (2014) Acupuncture in the treatment of cancer-related psychological symptoms. Integr Cancer Ther 13(5):371–385
33. Pandya KJ, Raubertas RF, Flynn PJ et al (2000) Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 132:788–793
34. Goldberg RM, Loprinzi CL, O’Fallon JR et al (1994) Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 12:155–158
35. Kelly CM, Juurlink DN, Gomes T et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 8(340):c693
36. Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764
37. Henry NL, Stearns V, Flockhart DA et al (2008) Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 165:1251–1255
38. Newton KM, Carpenter JS, Guthrie KA et al (2014) Methods for the design of vasomotor symptom trials: the menopausal strategies: finding lasting answers to symptoms and health network. Menopause 21(1):45–58